ICU Medical

ICU Medical, Inc. engages in the development, manufacture, and sale of innovative medical devices used in vascular therapy and critical care applications. Its product portfolio includes intravenous smart pumps, sets, connectors, closed transfer devices for hazardous drugs, cardiac monitoring systems, IV solutions, IV smart pumps with pain management and safety software technology, dedicated and non-dedicated IV sets and needle-free connectors. The company was founded by George A. Lopez in 1984 and is headquartered in San Clemente, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ICU Medical reports mixed Q4 results, eyes mid-single-digit growth

ICU Medical's Q4 2022 performance showcased mixed results, with revenue declines in legacy ICU Medical offset by improvements in Infusion Systems and Vital Care at Smiths Medical.
The company provided 2023 guidance with expectations of mid-single-digit revenue growth, improved gross margin, and a focus on addressing inflationary pressures and controlling costs.
Challenges included revenue shortfalls, supply interruptions, and concerns about operating margins, while opportunities exist in addressing FX impacts, regaining lost revenues, and enhancing operational efficiency.
Overall, ICU Medical remains focused on driving business performance, maintaining customer attention, and creating value through strategic realignment and operational synergies.

ICU Medical reports robust Q1 performance amidst segment-specific challenges

ICU Medical delivered a strong Q1 performance with revenue growth across segments and improved profitability metrics, showcasing operational strength.
While facing challenges in the Vascular Access segment, the company aims for growth in Consumables and maintains a positive outlook for the year.
Opportunities for revenue growth and financial optimization through operational efficiency improvements and strategic initiatives highlight potential avenues for future success.

ICU Medical reports Q2 earnings, adjusts guidance, focuses on stability

ICU Medical's Q2 2023 earnings call highlighted financial results, ongoing integration efforts, and a focus on stability and growth. The company remains confident in recapturing market share over time and aims for a full-year gross margin target of 37%.

ICU Medical reports Q3 results, focuses on growth and efficiency

ICU Medical reported mixed Q3 2023 financial results with adjusted revenues of $547 million and a 7% decrease in GAAP revenue year-over-year.
The company demonstrated strengths in maintaining a 36% adjusted gross margin, positive free cash flow, and a focus on operational efficiency.
Challenges included revenue declines in certain business segments and the need to address analyst concerns regarding margins and revenue growth.
Opportunities lie in product innovation, cash flow optimization, and a commitment to driving revenue growth and operational efficiency for long-term success.

ICU Medical reports solid Q4 results, focuses on margin improvement

ICU Medical's Q4 performance showed revenue growth and strong cash flow, with a focus on margin improvement and revenue growth in 2024. Challenges include competitive pump market dynamics and inventory drawdown impact on margins. The company aims to capitalize on opportunities for inventory reductions and margin enhancement.

ICU Medical reports steady Q1 growth, focuses on operational efficiency

ICU Medical's Q1 2024 performance showed steady revenue growth and improved margins driven by operational efficiencies. While facing challenges in certain segments, the company's focus on quality remediation and positive free cash flow generation bode well for future stability and growth.
Strategic opportunities exist in optimizing the Vital Care segment and leveraging strengths in the Consumables business. Continued emphasis on operational efficiency and product mix could position ICU Medical for sustained success in the healthcare market.

ICU Medical posts robust Q2 results, raises full-year guidance

ICU Medical delivered a strong Q2 performance with revenue growth and margin improvement.
The company's financial health is solid, with raised full-year guidance indicating confidence in future prospects.
Challenges include managing operating expenses and sustaining growth in a competitive market.
Strategic focus on innovation and efficiency presents opportunities for continued expansion and success.

ICU Medical posts robust Q3 results, raises guidance amid JV

ICU Medical's Q3 performance reflects strength in key segments and operational efficiency.
Challenges lie in the impact of the JV on financials and liquidity concerns from outstanding AR purchases.
Opportunities abound with raised guidance, strategic JV, and positive operational updates.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ICU Medical, Inc. develops, manufactures, and sells innovative medical products used in infusion therapy and critical care applications. Its product portfolio includes IV smart pumps, sets, connectors, closed system transfer devices for hazardous drugs, sterile IV solutions, cardiac monitoring systems, along with pain management and safety software technology designed to help meet clinical, safety and workflow goals. The company was founded by George A. Lopez in 1984 and is headquartered in San Clemente, CA.

ICU Medical, Inc. (ICUI) CEO Vivek Jain on Q3 2021 Results - Earnings Call Transcript

ICU Medical (ICUI) delivered earnings and revenue surprises of 15.64% and 6.96%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

ICU Medical (ICUI) Q3 Earnings and Revenues Surpass Estimates

SAN CLEMENTE, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced financial results for the quarter ended September 30, 2021.

ICU Medical, Inc. Announces Third Quarter 2021 Results

SAN CLEMENTE, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced the time of its third quarter 2021 earnings release and conference call.

ICU Medical, Inc. Announces Time of Third Quarter 2021 Earnings Conference Call

American Water Works

Cable One

Consolidated Communications Holdings

Fastenal

General Electric

Livanova

Las Vegas Sands

Paychex

Vonage Hlds

Expensive stocks with mediocre growth prospects can drop the most when the whole market starts to slide. These 10 stocks could be at high risk.

10 Expensive Stocks to Steer Clear Of

ICU Medical Inc (NASDAQ: ICUI), a California-based infusion therapy company, is voluntarily recalling one lot of an amino acid injection after reports of fibers, hair, and other particles of foreign materials were found. The Company had released a recall-related PR on September 3.

ICU Medical Pulls Amino Acid IV Products After Foreign Substances Found In Batch

A leading manufacturer of intravenous therapy solutions is about to get a lot bigger.

Why ICU Medical Stock Is Jumping Today

ICU Medical (NASDAQ: ICUI) shares are trading higher after the company announced it will acquire Smiths Medical division from Smiths Group PLC for $2.35 billion in cash and stock. The Smiths Medical business includes syringe and ambulatory infusion devices, vascular access, and vital care products.

Why ICU Medical Shares Surged Today

Today, a big acquisition deal has sent shares of ICU Medical more than 30% higher as investors and speculators buy into ICUI stock. The post ICUI Stock: What Is the Huge News Sending ICU Medical Soaring 35% Today appeared first on InvestorPlace.

ICUI Stock: What Is the Huge News Sending ICU Medical Soaring 35% Today

The stock price of ICU Medical Inc (NASDAQ: ICUI) increased over 35% during intraday trading. This is why it happened.

ICUI Stock: Over 35% Increase Explanation

ICU Medical, Inc. (ICUI) CEO Vivek Jain on ICU Medical's Smiths Medical Division Acquisition (Transcript)

ICU Medical Inc (NASDAQ: ICUI) has agreed to acquire Smiths Group plc's Medical division in a transaction that will create an IV therapy company and simplify customer workflow.  The Smiths Medical business includes syringe & ambulatory infusion devices, vascular access, and vital care products.

Smiths Group Divests Its Medical Division To ICU Medical In $2.4B Deal

The addition of Smiths Medical syringe and ambulatory infusion devices, vascular access, and vital care products into ICU Medical creates a leading infusion therapy company with a stronger global reach

ICU Medical, Inc. to acquire Smiths Medical division from Smiths Group plc for $2.35 billion in cash and stock plus the assumption of certain liabilities and a stock price performance-based earn-out

LAKE FOREST, Ill., Sept. 3, 2021 /PRNewswire/ -- ICU Medical, Inc. is voluntarily recalling one lot (2,112 units) of Aminosyn II, 15%, An Amino Acid Injection, Sulfite Free intravenous (IV) solution  to the hospital/user level due to the presence of visible particulate matter identified as fibers, hair, and proteinaceous material along with other particles.

ICU Medical Issues a Voluntary Nationwide Recall of Aminosyn II 15%, An Amino Acid Injection, Sulfite Free IV Solution Due to the Presence of Particulate Matter

ICU Medical, Inc.'s (ICUI) CEO Vivek Jain on Q2 2021 Results - Earnings Call Transcript

ICU Medical (ICUI) delivered earnings and revenue surprises of 14.63% and 5.02%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

ICU Medical (ICUI) Q2 Earnings and Revenues Beat Estimates

Company Updated FY 2021 Guidance Company Updated FY 2021 Guidance

ICU Medical, Inc. Announces Second Quarter 2021 Results

ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: ICU Medical (ICUI) Q2 Earnings Expected to Decline

ICU Medical's (ICUI) CEO Vivek Jain on Q1 2021 Results - Earnings Call Transcript

ICU Medical (ICUI) delivered earnings and revenue surprises of 5.88% and 4.55%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

ICU Medical (ICUI) Q1 Earnings and Revenues Top Estimates

SAN CLEMENTE, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced financial results for the quarter ended March 31, 2021.

ICU Medical, Inc. Announces First Quarter 2021 Results

Aflac

Conagra Brands

Hill-Rom Hlds

SJW Group

As bond yields pop and the rotation out of tech into recovery plays continues, Q.ai's Artificial Intelligence has brought you today's top buys.

Top Stocks To Buy Today As The Reopening Rotation Continues

ICU Medical, Inc. (ICUI) CEO Vivek Jain on Q4 2020 Results - Earnings Call Transcript

SAN CLEMENTE, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced financial results for the quarter ended December 31, 2020.

ICU Medical, Inc. Announces Fourth Quarter 2020 Results and Provides Fiscal Year 2021 Guidance

SAN CLEMENTE, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced that Company management will present at the Raymond James 42nd Annual Institutional Investors Conference, held virtually March 1-3, 2021.

News for ICU Medical Stock (ICUI)